MDMA-assisted Therapy Comprehensive Study by Therapy (Cognitive Behavioural Therapy, Dialectical Behaviour Therapy, Exposure Therapy, Group Therapy, Interpersonal Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospital, Clinics, Diagnostic Centres, Others) Players and Region - Global Market Outlook to 2026

MDMA-assisted Therapy Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global MDMA-assisted Therapy Market Overview:
PTSD is a common and debilitating condition with enormous social and economic costs that affects hundreds of millions of people each year. PTSD develops after a traumatic event such as a serious accident, injuries, or war. Memories can manifest as flashbacks or nightmares, forcing some people to relive terrifying events. There is no medication that can treat PTSD, but some medications can help with symptoms. This is where MDMA Therapy arises. MDMA is a psychoactive drug that acts as a stimulant and releases chemicals in your brain to give you energy, heighten your senses, and increase emotions such as self-awareness and empathy. MDMA -assisted therapy helps to treat PTSD Patients.

Growth Drivers
  • Growing Demand for Antidepressants
  • Increase in Number of Autistic Adults

Roadblocks
  • High Cost of MDMA Drugs and Therapy

Opportunities
  • Rising Investment in Healthcare Sector
  • Increasing Government Initiatives for MDMA Therapy Awareness

Challenges
  • Risk of MDMA Overdose
  • Lack of Awareness in Emerging Economies


Competitive Landscape:
The demand for MDMA-assisted Therapy is increasing. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position. Players are expected to focus on the creation of new compounds, which would likely drive the worldwide market forward over the forecast period.
Some of the key players profiled in the report are Numinus Wellness (Canada), ATAI Life Sciences (Germany), Seelos Therapeutics (United States), Awakn Life Sciences (Canada), Field Trip Health (Canada), Cybin (Canada), Novamind (Canada), Mount Sinai Health System (United States), COMPASS Pathways PLC (United Kingdom) and MindMed (United States). Analyst at AMA Research see Canada Players to retain maximum share of Global MDMA-assisted Therapy market by 2026. Considering Market by Therapy, the sub-segment i.e. Cognitive Behavioural Therapy will boost the MDMA-assisted Therapy market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the MDMA-assisted Therapy market. Considering Market by End User, the sub-segment i.e. Hospital will boost the MDMA-assisted Therapy market.

In September 2021 Awakn had announced the acquisition of MDMA Research Rights from Imperial College London. This information will aid Awakn's progress by allowing for a more efficient design and execution of its clinical programme. Awakn will now be able to move its clinical research into a phase IIb randomised controlled trial (RCT) in the United Kingdom. This is part of its strategy to obtain marketing authorization for MDMA to treat AUD in both the United Kingdom and the European Union, which has a population of 400 million people.

What Can be Explored with the MDMA-assisted Therapy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global MDMA-assisted Therapy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in MDMA-assisted Therapy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global MDMA-assisted Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in MDMA-assisted Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture and Capitalist, New entrants/investors, Analysts and Strategic Business Partners, Hospital, Clinics and End-use industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Therapy
  • Cognitive Behavioural Therapy
  • Dialectical Behaviour Therapy
  • Exposure Therapy
  • Group Therapy
  • Interpersonal Therapy
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User
  • Hospital
  • Clinics
  • Diagnostic Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand for Antidepressants
      • 3.2.2. Increase in Number of Autistic Adults
    • 3.3. Market Challenges
      • 3.3.1. Risk of MDMA Overdose
      • 3.3.2. Lack of Awareness in Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Emergence of Psychedelic Medicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global MDMA-assisted Therapy, by Therapy, Distribution Channel, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global MDMA-assisted Therapy (Value)
      • 5.2.1. Global MDMA-assisted Therapy by: Therapy (Value)
        • 5.2.1.1. Cognitive Behavioural Therapy
        • 5.2.1.2. Dialectical Behaviour Therapy
        • 5.2.1.3. Exposure Therapy
        • 5.2.1.4. Group Therapy
        • 5.2.1.5. Interpersonal Therapy
        • 5.2.1.6. Others
      • 5.2.2. Global MDMA-assisted Therapy Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Australia
          • 5.2.2.2.6. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global MDMA-assisted Therapy (Price)
  • 6. MDMA-assisted Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Numinus Wellness (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ATAI Life Sciences (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Seelos Therapeutics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Awakn Life Sciences (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Field Trip Health (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cybin (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novamind (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mount Sinai Health System (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. COMPASS Pathways PLC (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. MindMed (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global MDMA-assisted Therapy Sale, by Therapy, Distribution Channel, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global MDMA-assisted Therapy (Value)
      • 7.2.1. Global MDMA-assisted Therapy by: Therapy (Value)
        • 7.2.1.1. Cognitive Behavioural Therapy
        • 7.2.1.2. Dialectical Behaviour Therapy
        • 7.2.1.3. Exposure Therapy
        • 7.2.1.4. Group Therapy
        • 7.2.1.5. Interpersonal Therapy
        • 7.2.1.6. Others
      • 7.2.2. Global MDMA-assisted Therapy Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Australia
          • 7.2.2.2.6. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global MDMA-assisted Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. MDMA-assisted Therapy: by Therapy(USD Million)
  • Table 2. MDMA-assisted Therapy Cognitive Behavioural Therapy , by Region USD Million (2015-2020)
  • Table 3. MDMA-assisted Therapy Dialectical Behaviour Therapy , by Region USD Million (2015-2020)
  • Table 4. MDMA-assisted Therapy Exposure Therapy , by Region USD Million (2015-2020)
  • Table 5. MDMA-assisted Therapy Group Therapy , by Region USD Million (2015-2020)
  • Table 6. MDMA-assisted Therapy Interpersonal Therapy , by Region USD Million (2015-2020)
  • Table 7. MDMA-assisted Therapy Others , by Region USD Million (2015-2020)
  • Table 8. South America MDMA-assisted Therapy, by Country USD Million (2015-2020)
  • Table 9. South America MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 10. South America MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 11. South America MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 12. Brazil MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 13. Brazil MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 14. Brazil MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 15. Argentina MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 16. Argentina MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 17. Argentina MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 18. Rest of South America MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 19. Rest of South America MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 20. Rest of South America MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 21. Asia Pacific MDMA-assisted Therapy, by Country USD Million (2015-2020)
  • Table 22. Asia Pacific MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 23. Asia Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 24. Asia Pacific MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 25. China MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 26. China MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 27. China MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 28. Japan MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 29. Japan MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 30. Japan MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 31. India MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 32. India MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 33. India MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 34. South Korea MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 35. South Korea MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 36. South Korea MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 37. Australia MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 38. Australia MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 39. Australia MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 40. Rest of Asia-Pacific MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 41. Rest of Asia-Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 42. Rest of Asia-Pacific MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 43. Europe MDMA-assisted Therapy, by Country USD Million (2015-2020)
  • Table 44. Europe MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 45. Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 46. Europe MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 47. Germany MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 48. Germany MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 49. Germany MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 50. France MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 51. France MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 52. France MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 53. Italy MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 54. Italy MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 55. Italy MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 56. United Kingdom MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 57. United Kingdom MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 58. United Kingdom MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 59. Netherlands MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 60. Netherlands MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 61. Netherlands MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 62. Rest of Europe MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 63. Rest of Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 64. Rest of Europe MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 65. MEA MDMA-assisted Therapy, by Country USD Million (2015-2020)
  • Table 66. MEA MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 67. MEA MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 68. MEA MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 69. Middle East MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 70. Middle East MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 71. Middle East MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 72. Africa MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 73. Africa MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 74. Africa MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 75. North America MDMA-assisted Therapy, by Country USD Million (2015-2020)
  • Table 76. North America MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 77. North America MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 78. North America MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 79. United States MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 80. United States MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 81. United States MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 82. Canada MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 83. Canada MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 84. Canada MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 85. Mexico MDMA-assisted Therapy, by Therapy USD Million (2015-2020)
  • Table 86. Mexico MDMA-assisted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 87. Mexico MDMA-assisted Therapy, by End User USD Million (2015-2020)
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. MDMA-assisted Therapy: by Therapy(USD Million)
  • Table 99. MDMA-assisted Therapy Cognitive Behavioural Therapy , by Region USD Million (2021-2026)
  • Table 100. MDMA-assisted Therapy Dialectical Behaviour Therapy , by Region USD Million (2021-2026)
  • Table 101. MDMA-assisted Therapy Exposure Therapy , by Region USD Million (2021-2026)
  • Table 102. MDMA-assisted Therapy Group Therapy , by Region USD Million (2021-2026)
  • Table 103. MDMA-assisted Therapy Interpersonal Therapy , by Region USD Million (2021-2026)
  • Table 104. MDMA-assisted Therapy Others , by Region USD Million (2021-2026)
  • Table 105. South America MDMA-assisted Therapy, by Country USD Million (2021-2026)
  • Table 106. South America MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 107. South America MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 108. South America MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 109. Brazil MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 110. Brazil MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 111. Brazil MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 112. Argentina MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 113. Argentina MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 114. Argentina MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 115. Rest of South America MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 116. Rest of South America MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 117. Rest of South America MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 118. Asia Pacific MDMA-assisted Therapy, by Country USD Million (2021-2026)
  • Table 119. Asia Pacific MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 120. Asia Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 121. Asia Pacific MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 122. China MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 123. China MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 124. China MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 125. Japan MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 126. Japan MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 127. Japan MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 128. India MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 129. India MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 130. India MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 131. South Korea MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 132. South Korea MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 133. South Korea MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 134. Australia MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 135. Australia MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 136. Australia MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 137. Rest of Asia-Pacific MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 138. Rest of Asia-Pacific MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 139. Rest of Asia-Pacific MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 140. Europe MDMA-assisted Therapy, by Country USD Million (2021-2026)
  • Table 141. Europe MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 142. Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 143. Europe MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 144. Germany MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 145. Germany MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 146. Germany MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 147. France MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 148. France MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 149. France MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 150. Italy MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 151. Italy MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 152. Italy MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 153. United Kingdom MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 154. United Kingdom MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 155. United Kingdom MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 156. Netherlands MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 157. Netherlands MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 158. Netherlands MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 159. Rest of Europe MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 160. Rest of Europe MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 161. Rest of Europe MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 162. MEA MDMA-assisted Therapy, by Country USD Million (2021-2026)
  • Table 163. MEA MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 164. MEA MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 165. MEA MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 166. Middle East MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 167. Middle East MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 168. Middle East MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 169. Africa MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 170. Africa MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 171. Africa MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 172. North America MDMA-assisted Therapy, by Country USD Million (2021-2026)
  • Table 173. North America MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 174. North America MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 175. North America MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 176. United States MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 177. United States MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 178. United States MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 179. Canada MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 180. Canada MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 181. Canada MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 182. Mexico MDMA-assisted Therapy, by Therapy USD Million (2021-2026)
  • Table 183. Mexico MDMA-assisted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 184. Mexico MDMA-assisted Therapy, by End User USD Million (2021-2026)
  • Table 185. Research Programs/Design for This Report
  • Table 186. Key Data Information from Secondary Sources
  • Table 187. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global MDMA-assisted Therapy: by Therapy USD Million (2015-2020)
  • Figure 5. South America MDMA-assisted Therapy Share (%), by Country
  • Figure 6. Asia Pacific MDMA-assisted Therapy Share (%), by Country
  • Figure 7. Europe MDMA-assisted Therapy Share (%), by Country
  • Figure 8. MEA MDMA-assisted Therapy Share (%), by Country
  • Figure 9. North America MDMA-assisted Therapy Share (%), by Country
  • Figure 10. Global MDMA-assisted Therapy share by Players 2020 (%)
  • Figure 11. Global MDMA-assisted Therapy share by Players (Top 3) 2020(%)
  • Figure 12. Global MDMA-assisted Therapy share by Players (Top 5) 2020(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Numinus Wellness (Canada) Revenue, Net Income and Gross profit
  • Figure 15. Numinus Wellness (Canada) Revenue: by Geography 2020
  • Figure 16. ATAI Life Sciences (Germany) Revenue, Net Income and Gross profit
  • Figure 17. ATAI Life Sciences (Germany) Revenue: by Geography 2020
  • Figure 18. Seelos Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Seelos Therapeutics (United States) Revenue: by Geography 2020
  • Figure 20. Awakn Life Sciences (Canada) Revenue, Net Income and Gross profit
  • Figure 21. Awakn Life Sciences (Canada) Revenue: by Geography 2020
  • Figure 22. Field Trip Health (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Field Trip Health (Canada) Revenue: by Geography 2020
  • Figure 24. Cybin (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Cybin (Canada) Revenue: by Geography 2020
  • Figure 26. Novamind (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Novamind (Canada) Revenue: by Geography 2020
  • Figure 28. Mount Sinai Health System (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mount Sinai Health System (United States) Revenue: by Geography 2020
  • Figure 30. COMPASS Pathways PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. COMPASS Pathways PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 32. MindMed (United States) Revenue, Net Income and Gross profit
  • Figure 33. MindMed (United States) Revenue: by Geography 2020
  • Figure 34. Global MDMA-assisted Therapy: by Therapy USD Million (2021-2026)
  • Figure 35. South America MDMA-assisted Therapy Share (%), by Country
  • Figure 36. Asia Pacific MDMA-assisted Therapy Share (%), by Country
  • Figure 37. Europe MDMA-assisted Therapy Share (%), by Country
  • Figure 38. MEA MDMA-assisted Therapy Share (%), by Country
  • Figure 39. North America MDMA-assisted Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Numinus Wellness (Canada)
  • ATAI Life Sciences (Germany)
  • Seelos Therapeutics (United States)
  • Awakn Life Sciences (Canada)
  • Field Trip Health (Canada)
  • Cybin (Canada)
  • Novamind (Canada)
  • Mount Sinai Health System (United States)
  • COMPASS Pathways PLC (United Kingdom)
  • MindMed (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 242 Pages 70 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The MDMA-assisted Therapy market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global MDMA-assisted Therapy market are Numinus Wellness (Canada), ATAI Life Sciences (Germany), Seelos Therapeutics (United States), Awakn Life Sciences (Canada), Field Trip Health (Canada), Cybin (Canada), Novamind (Canada), Mount Sinai Health System (United States), COMPASS Pathways PLC (United Kingdom) and MindMed (United States), to name a few.
"Emergence of Psychedelic Medicine" is seen as one of major influencing trends for MDMA-assisted Therapy Market during projected period 2020-2026.

Know More About Global MDMA-assisted Therapy Market Report?